Erin Kopp
Nurse Practitioner · Duarte, CANPI 1629381827
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,156 of the $107,471 with a category attached, or 66.2%. Incyte Corporation accounts for 87.9% of it on its own, with 24 other manufacturers making up the rest. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $332.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$94K
- Kyowa Kirin, Inc.$9K
- Kadmon Pharmaceuticals LLC$952
- AstraZeneca$592
- Bristol Myers Squibb$255
- Genentech USA, Inc.$246
- plus $2K from 19 others
What the payments were for
- Consulting fees$5,7005%
- Speaking & faculty fees$71,15666%
- Travel & lodging$24,74423%
- Food & beverage$5,7735%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 193 | $94,453 |
| Kyowa Kirin, Inc. | 21 | $9,381 |
| Kadmon Pharmaceuticals LLC | 1 | $952 |
| AstraZeneca(2 entities) | 22 | $592 |
| Bristol Myers Squibb | 10 | $255 |
| Genentech USA, Inc. | 12 | $246 |
| Astellas Pharma US Inc | 5 | $233 |
| Merck | 8 | $157 |
| Amgen | 8 | $155 |
| Daiichi Sankyo Inc. | 6 | $129 |
| Johnson & Johnson | 5 | $115 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $114 |
| AbbVie | 4 | $94 |
| Sanofi | 4 | $82 |
| Jazz Pharmaceuticals Inc. | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 1 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Taiho Oncology, Inc. | 1 | $55 |
| Pfizer | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Melinta Therapeutics, LLC | 2 | $47 |
| Seagen Inc. | 2 | $41 |
| Genmab U.S., Inc. | 1 | $26 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Servier Pharmaceuticals LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,471 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 13 | $230,920 |
| Potassium Chloride | 11 | $766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $114 | $230,92013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Duarte
- Kathleen BurnsDuarte$164K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.